SARS-CoV-2 seroprevalence among Canadian blood donors : the advance of Omicron
SARS-CoV-2 seroprevalence among Canadian blood donors : the advance of Omicron
Simple item page
Full item details
- dc.contributor.author
- O’Brien, Sheila F.
- Caffrey, Niamh
- Yi, Qi-Long
- Pambrun, Chantale
- Drews, Steven J.
- dc.date.accessioned
- 2025-02-06T21:11:54Z
- dc.date.available
- 2025-02-06T21:11:54Z
- dc.date.issued
- 2022-10-25
- dc.description.abstract - en
- With the emergence of the SARS-CoV-2 Omicron variant in late 2021, Canadian public health case/contact testing was scaled back due to high infection rates with milder symptoms in a highly vaccinated population. We monitored the seroprevalence of SARS-CoV-2 nucleocapsid (anti-N) and spike protein (anti-S) antibodies in blood donors across Canada from September 2021 to June 2022 in 202,123 randomly selected samples. Multivariable logistic regression of anti-N positivity with month, age, sex, racialization, region, material and social deprivation (based on postal code) identified as independent predictors. Piece-wise logistic regression analysed the association between anti-S concentration and month, and anti-N/anti-S positivity. Infection-related seroprevalence (anti-N positive) was 4.38% (95% CI: 3.96, 4.81) in September reaching 50.70% (50.15, 52.16) in June; nearly 100% were anti-S positive throughout. Anti-N positivity was associated with younger age, male sex, the Alberta and Prairies regions, greater material deprivation and less social deprivation (p < 0.001). Anti-S concentration was high initially (3306 U/mL, IQR 4280 U/mL), increased to (13,659 U/mL, IQR 28,224 U/mL) by June (p < 0.001), following the pattern of deployment of the third and fourth vaccine doses and was higher in those that were anti-N positive (p < 0.001). Despite already high vaccination-related seroprevalence, infection-related seroprevalence increased dramatically with the emergence of the Omicron SARS-CoV-2 variant.
- dc.description.sponsorship
- This research was funded by the Government of Canada through the COVID-19 Immunity Task Force.
- dc.identifier.doi
- https://doi.org/10.3390/v14112336
- dc.identifier.issn
- 1999-4915
- dc.identifier.pubmedID
- 36366432
- dc.identifier.uri
- https://open-science.canada.ca/handle/123456789/3404
- dc.language.iso
- en
- dc.publisher - en
- MDPI
- dc.rights - en
- Creative Commons Attribution 4.0 International (CC BY 4.0)
- dc.rights - fr
- Creative Commons Attribution 4.0 International (CC BY 4.0)
- dc.rights.openaccesslevel - en
- Gold
- dc.rights.openaccesslevel - fr
- Or
- dc.rights.uri - en
- https://creativecommons.org/licenses/by/4.0/
- dc.rights.uri - fr
- https://creativecommons.org/licenses/by/4.0/deed.fr
- dc.subject - en
- Health
- Blood supply
- Epidemiology
- Coronavirus diseases
- dc.subject - fr
- Santé
- Approvisionnement en sang
- Épidémiologie
- Maladie à coronavirus
- dc.subject.en - en
- Health
- Blood supply
- Epidemiology
- Coronavirus diseases
- dc.subject.fr - fr
- Santé
- Approvisionnement en sang
- Épidémiologie
- Maladie à coronavirus
- dc.title - en
- SARS-CoV-2 seroprevalence among Canadian blood donors : the advance of Omicron
- dc.type - en
- Article
- dc.type - fr
- Article
- local.acceptedmanuscript.articlenum
- 2336
- local.article.journalissue
- 11
- local.article.journaltitle - en
- Viruses
- local.article.journalvolume
- 14
- local.pagination
- 1-15
- local.peerreview - en
- Yes
- local.peerreview - fr
- Oui
Download(s)
Original bundle
1 - 1 of 1
Name: sars-cov-2-seroprevalence-canadian-blood-donors-omicron.pdf
Size: 8.77 MB
Format: PDF
Collection(s)